Switchable Living Drug Shrinks Tumors in Resistant Melanoma
Two early trials of an engineered tumor-fighting cell therapy found responses in two-thirds of 15 patients at the chosen dose, without the harsh drug IL-2.
Switchable Living Drug Shrinks Tumors in Resistant Melanoma
Digital Twins of the Immune System in Pregnancy
Catch Up on Sleep: Rebound May Reduce Mortality
MOGAD Treatment: Acute Care, Relapse Prevention, and Emerging Therapies
Ticks and Autoimmune Disease: Discovery of Dual Evasin
Ageing Immune Memory Cells: How Immunity Adapts Over Time
How Norovirus Hijacks Gut Bacteria to Spread Infection
When Immune Cells Help Cancer: CCL3 and Aged Neutrophils Across Cancer Types
Ovarian Cancer Cell Invasion and Metastasis: The Role of Mesothelial Cells
Protein Intake and Liver Cancer: What the Latest Research Reveals